Company: PSTV
Filing Date: 2025-08-04
Form Type: DRS
Source: 0000950123-25-006916
Chunk: 7

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-04
Form: DRS
Chunk 7
---
 selling stockholder | Up to 33,000,000 shares of our common stock, subject to certain limitations described in this prospectus, consisting of (a) [31,387,097] shares of common stock which we may issue and sell to Lincoln Park from time to time, at our sole 
 discretion, during the 36-month period that began on the Commencement Date in accordance with the Purchase Agreement, and (b) [1,612,903] shares of common stock, which are the Initial Commitment Shares, for                             
 which we received no cash consideration.                                                                                                                                                                                                   |

| Shares of our common stock outstanding prior to this offering (as of July 30, 2025) | 99,264,526 shares of our common stock. |

| Shares of our common stock to be outstanding 
 after this offering                          | 132,264,526 shares of our common stock, assuming the sale of all the shares of common stock registered hereunder to Lincoln Park under the Purchase Agreement. The actual number of shares outstanding after this offering will vary depending upon 
 the actual number of shares we sell to Lincoln Park under the Purchase Agreement after the date of this prospectus.                                                                                                                                 |

| Use of proceeds | We will receive no proceeds from the sale of shares of our common stock by Lincoln Park in this offering. We may receive, initially, aggregate gross proceeds of up to the Initial Available Amount and, upon receipt of the full amount thereof,        
 additional aggregate gross proceeds of up to the Additional Available Amount (for total aggregate gross proceeds of up to the Total Available Amount) from sales of shares of our common stock we make to Lincoln Park, if any, pursuant to the Purchase 
 Agreement, assuming that we sell the full amount of our common stock that we have the right, but not the obligation to sell to Lincoln Park under the Purchase Agreement. Through August [●], 2025, we have received approximately $[2.8] million        
 under the Purchase Agreement. Any proceeds that we receive from sales of shares of our common stock to Lincoln Park under the Purchase Agreement will be used for working capital and general corporate purposes and to the extent required, for         
 Make-Whole Repayment (as defined in the “Use of Proceeds” section). See “Use of Proceeds.”                                                                                                                                                               |

| Nasdaq symbol for our common stock | “PSTV” |

| Risk factors | This investment involves a high degree of risk. See “Risk Factors” beginning on page 4 of this prospectus for a